← Leaderboards
Hamid Ghandehari
Utah State Higher Education System--University Of Utah
$11,617,654
Attributed
$13,380,994
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,380,994 · 13
By mechanism
R01$11,028,854 · 6
R42$1,495,828 · 1
R41$699,237 · 4
R21$141,075 · 1
R13$16,000 · 1
Top collaborators
- Darwin Leroy Cheney6 shared
- Siam Oottamasathien5 shared
Most similar at Utah State Higher Education System--University Of Utah
Same institution · by research overlap
- Jindrich N. Kopecek$15,322,903
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroToxic EffectResponseBiodistributionPropertyPolymersDesignProteinsBiologicalBaseDrug Delivery SystemsTissuesDrug KineticsMediatingChronicEvaluationAffectPharmaceutical PreparationsChargeCharacteristicsHydrogelsMolecular WeightEngineering
Grant awards (48)
BIOLOGICAL FATE AND BIOCOMPATIBILITY OF SILICA-BASED NANOCONSTRUCTS$461,025
R01 · FY2025 · ES · contact PI
BIOLOGICAL FATE AND BIOCOMPATIBILITY OF SILICA-BASED NANOCONSTRUCTS$485,659
R01 · FY2024 · ES · contact PI
BIOLOGICAL FATE AND BIOCOMPATIBILITY OF SILICA-BASED NANOCONSTRUCTS$501,303
R01 · FY2023 · ES · contact PI
Localized delivery of glycosaminoclycan ethers for the treatment of radiation-induced proctitis$304,089
R01 · FY2023 · CA · contact PI
BIOLOGICAL FATE AND BIOCOMPATIBILITY OF SILICA-BASED NANOCONSTRUCTS$480,633
R01 · FY2022 · ES · contact PI
Localized delivery of glycosaminoclycan ethers for the treatment of radiation-induced proctitis$335,171
R01 · FY2022 · CA · contact PI
Localized delivery of glycosaminoclycan ethers for the treatment of radiation-induced proctitis$342,013
R01 · FY2021 · CA · contact PI
Localized delivery of glycosaminoclycan ethers for the treatment of radiation-induced proctitis$342,013
R01 · FY2020 · CA · contact PI
Localized delivery of glycosaminoclycan ethers for the treatment of radiation-induced proctitis$307,566
R01 · FY2019 · CA · contact PI
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$1,450
R42 · FY2019 · CA · contact PI
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$399,441
R42 · FY2018 · CA · contact PI
Biological Fate and Biocompatability of Dendritic and Silica-Based Nanoconstructs$335,250
R01 · FY2018 · ES · contact PI
Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms$150,000
R41 · FY2018 · NS · contact PI
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$694,475
R42 · FY2017 · CA · contact PI
Biological Fate and Biocompatability of Dendritic and Silica-Based Nanoconstructs$335,250
R01 · FY2017 · ES · contact PI
Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms$250,000
R41 · FY2017 · NS · contact PI
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$400,462
R42 · FY2016 · CA · contact PI
Biological Fate and Biocompatability of Dendritic and Silica-Based Nanoconstructs$335,250
R01 · FY2016 · ES · contact PI
Biological Fate and Biocompatability of Dendritic and Silica-Based Nanoconstructs$335,250
R01 · FY2015 · ES · contact PI
Biological Fate and Biocompatability of Dendritic and Silica-Based Nanoconstructs$335,250
R01 · FY2014 · ES · contact PI
Engineering Polymers for Gene Therapy of Head Cancer$308,161
R01 · FY2014 · CA · contact PI
Engineering Polymers for Gene Therapy of Head Cancer$299,030
R01 · FY2013 · CA · contact PI
Engineering Polymers for Gene Therapy of Head Cancer$318,544
R01 · FY2012 · CA · contact PI
In-situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$100,000
R41 · FY2012 · CA · contact PI
Engineering Polymers for Gene Therapy of Head Cancer$305,332
R01 · FY2011 · CA · contact PI
Dendritic Biomaterials for Oral Delivery of Chemotherapeutics$296,344
R01 · FY2010 · EB · contact PI
Biological fate and biocompatibility of dendritic and silica-based nanoconstructs$268,540
R01 · FY2010 · DE · contact PI
Engineering Polymers for Gene Therapy of Head Cancer$134,322
R01 · FY2010 · CA · contact PI
Targeted Polymeric Combination Delivery for Treatment of Ovarian Cancer$100,000
R41 · FY2010 · CA · contact PI
Biological fate and biocompatibility of dendritic and silica-based nanoconstructs$306,451
R01 · FY2009 · DE · contact PI
Dendritic Biomaterials for Oral Delivery of Chemotherapeutics$299,337
R01 · FY2009 · EB · contact PI
Polymers for Targeted Delivery of Angiogenic Inhibitors$297,654
R01 · FY2009 · EB · contact PI
Biological fate and biocompatibility of dendritic and silica-based nanoconstructs$310,362
R01 · FY2008 · DE · contact PI
Dendritic Biomaterials for Oral Delivery of Chemotherapeutics$299,337
R01 · FY2008 · EB · contact PI
Engineering Polymers For Gene Therapy of Head Cancer$281,835
R01 · FY2008 · CA · contact PI
Polymers for Targeted Delivery of Angiogenic Inhibitors$241,733
R01 · FY2008 · EB · contact PI
Biological fate and biocompatibility of dendritic and silica-based nanoconstructs$388,086
R01 · FY2007 · DE · contact PI
Dendritic Biomaterials for Oral Delivery of Chemotherapeutics$313,375
R01 · FY2007 · EB · contact PI
Polymers for Targeted Delivery of Angiogenic Inhibitors$194,058
R01 · FY2007 · EB · contact PI
Polymers for Targeted Delivery of Angiogenic Inhibitors$100,514
R01 · FY2007 · EB · contact PI
Biological fate and biocompatibility of dendritic and silica-based nanoconstructs$1
R01 · FY2007 · DE · contact PI
Engineering Polymers For Gene Therapy of Head Cancer$286,396
R01 · FY2006 · CA · contact PI
Polymers for Targeted Delivery of Angiogenic Inhibitors$279,761
R01 · FY2006 · EB · contact PI
Recombinant Polymers for Systemic Cancer Gene Therapy$141,075
R21 · FY2006 · CA · contact PI
Engineering Polymers For Gene Therapy of Head Cancer$263,959
R01 · FY2005 · CA
Third Annual Nanomedicine and Drug Delivery Symposium$16,000
R13 · FY2005 · EB
Polymeric delivery of enzymes and prodrugs for cancer$76,116
R41 · FY2002 · CA
Polymeric delivery of enzymes and prodrugs for cancer$23,121
R41 · FY2002 · CA